Background: Very-low-density lipoprotein (VLDL) in vitro can induce foam cell formation in human mesangial cells. Lipoprotein lipase (LPL) expressed in the arterial wall plays a key role in atherogenesis by actions of enzymolysis and ‘molecular bridge’, and, thereby, leads to the formation of lipid-loaded foam cells. It is known that LPL is expressed by glomerular mesangial cells. This study was designed to investigate if LPL plays a role in VLDL-induced lipid accumulation in human mesangial cells and its underlying mechanism. Methods: Human wild-type LPL (hLPLwt), catalytically inactive LPL (hLPL194) or control alkaline phosphatase (hAP) were expressed in human mesangial cell line (HMCLs) via adenoviral vectors. Orlistat (tetrahydrolipstatin), a specific inhibitor of the lipoidolytic activity of endogenous LPL, and heparinase, which degrades cell-surface heparan sulfate proteoglycans, were also used to estimate the role of either the enzymolysis or ‘molecular bridge’ actions of LPL in the uptake of VLDL. Anti-low-density lipoprotein receptor (LDLr) antibody and anti-LDL receptor-related protein antibody were used to evaluate the effect of lipoprotein receptors on VLDL-induced lipid accumulation in HMCLs. Cellular lipid deposition was visualized by Oil Red O staining and analyzed quantitatively by standard enzymatic procedures. LPL protein expression and activity were measured by Western blot and a chemical analysis, respectively. Results: VLDL induced triglyceride accumulation in HMCLs in a time- and dose-dependent manner. Compared with Ad-hAP transfected HMCLs, cellular triglyceride content increased 4.55-fold (p < 0.05) in Ad-hLPLwt-transfected HMCLs and 1.52-fold (p < 0.05) in Ad-hLPL194-transfected HMCLs. Triglyceride accumulation in response to VLDL was mostly blocked by orlistat. Pretreatment of the cells with heparinase slightly reduced cellular triglyceride accumulation in the present of high concentrations of VLDL. The blockade of some lipoprotein receptors, such as LDLr, did not significantly reduce cellular triglyceride accumulation. LPL expression was upregulated by VLDL. Conclusions: VLDL-induced triglyceride accumulation in human mesangial cells is mainly mediated by LPL, and the enzymolysis action of LPL could be a major factor in this process. These results suggest that LPL may be an important factor participating in the initiation and progression of VLDL-mediated lipid renal injury.

Keywords:
Hyperlipidemia, Glomerular sclerosis, Lipoprotein lipase, Mesangial cells, Very-low-density lipoprotein
1.
Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Weiss L, Alaupovic P: Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998;9:1482–1488.
2.
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S: Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int 2002;62:1743–1749.
3.
Diamond JR: Effect of lipid abnormalities on the progression of renal damage: analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991;39(suppl 31):S29–S34.
4.
Suzaki K, Kobori S, Ueno S, Uehara M, Kayashima T, Takeda H, Fukuda S, Takahashi K, Nakamura N, Uzawa H, Shichiri M: Effect of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephritic syndrome and diabetes mellitus. Atherosclerosis 1990;80:181–189.
5.
Anami Y, Kobori S, Sakai M, Kasho M, Nishikawa T, Yano T, Matsuda H, Matsumura T, Takemura T, Shichiri M: Human β-migrating very low density lipoprotein induces foam cell formation in human mesangial cells. Atherosclerosis 1997;135:225–234.
6.
Mead JR, Irvine SA, Ramji DP: Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 2002;80:753–769.
7.
Camps L, Reina M, Llobera M, Vilaro S, Olivecrona T: Lipoprotein lipase: cellular origin and functional distribution. Am J Physiol 1990;258:c673–c681.
8.
Irvine SA, Martin J, Hughes TR, Ramji DP: Lipoprotein lipase is expressed by glomerular mesangial cells. Int J Biochem Cell Biol 2006;38:12–16.
9.
Lindqvist P, Ostlund-Lindqvist AM, Witztum JL, Steinberg D, Little JA: The role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins by macrophages. J Biol Chem 1983;258:9086–9092.
10.
Evans AJ, Sawyez CG, Wolfe BM, Connelly PW, Maguire GF, Huff MW: Evidence that cholesterol ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms. J Lipid Res 1993;34:703–717.
11.
Enerback S, Gimble JM: Lipoprotein lipase gene expression: physiological regulators at the transcriptional and post-transcriptional level. Biochim Biophys Acta 1993;1169:107–125.
12.
Medh JD, Bowen SL, Fry GL, Ruben S, Andracki M, Inoue I, Lalouel JM, Strickland DK, Chappell DA: Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro. J Biol Chem 1996;271:17073–17080.
13.
Sraer JD, Delarue F, Hagege J, Feunteun J, Pinet F, Nguyen G, Rondeau E: Stable cell lines of T-SV 40 immortalized human glomerular mesangial cells. Kidney Int 1996;49:267–270.
14.
Ruan XZ, Varghese Z, Fernando R, Moorhead JF: Cytokine regulation of low-density lipoprotein receptor gene transcription in human mesangial cells. Nephrol Dial Transplant 1998;13:1391–1397.
15.
Zhang AH, Gao S, Fan JL, Huang W, Zhao TQ, Liu George: Increased plasma HDL cholesterol levels and biliary cholesterol excretion in hamster by LCAT overexpression. FEBS Lett 2004;570:25–29.
16.
Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345–1353.
17.
Liu G, Ashbourne-Excoffon KJ, Wilson JE, McManus BM, Rogers QR, Miao L, Kastelein JJ, Lewis ME, Hayden MR: Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. Hum Gene Ther 2000;11:21–32.
18.
Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ: Subendothelial retention of lipoprotein(a): evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 1997;100:867–874.
19.
Folch J, Lees M, Sloane-Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497–509.
20.
McGowan MW, Artiss JD, Strandbergh DR, Zak B: A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983;29:538–542.
21.
Nilsson-Ehle P, Schotz MC: A stable, radioactive substrate emulsion for assay of lipoprotein lipase. J Lipid Res 1976;17:536–541.
22.
Palmer AM, Nova E, Anil E, Jackson K, Bateman P, Wolstencroft E, Walliams CM, Yaqoob P: Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages. Atherosclerosis 2005;180:233–244.
23.
Lookene A, Skottova N, Olivecrona G: Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat)®. Eur J Biochem 1994;222:395–403.
24.
Skarlatos SI, Dicheck HL, Fojo SS, Brewer HB, Kruth HS: Absence of triglyceride accumulation in lipoprotein lipase-deficient human monocyte-macrophages incubated with human very low density lipoprotein. J Clin Endocrinol Metab 1993;76:793–796.
25.
Evans AJ, Sawyez CG, Wolfe BM, Connelly PW, Maguire GF, Huff MW: Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms. J Lipid Res 1993;34:703–717.
26.
Schonfeld G, Patsch W, Pfleger B, Witztum JL, Weidman SW: Lipolysis produces changes in the immunoreactivity and cell reactivity of very low density lipoproteins. J Clin Invest 1979;64:1288–1297.
27.
Evans AJ, Sawyez CG, Wolfe BM, Huff MW: Lipolysis is a prerequisite for lipid accumulation in HepG2 cells induced by large hypertriglyceridemic very low density lipoproteins. J Biol Chem 1992;267:10743–10751.
28.
Stevenson FT, Shearer GC, Atkinson DN: Lipoprotein-stimulated mesangial cell proliferation and gene expression are regulated by lipoprotein lipase. Kidney Int 2001;59:2062–2068.
29.
Wang JY, Xian XD, Huang W, Chen L, Wu LI, Fan JL, Ross C, Hayden MR, Liu G: Expression of LPL in endothelial-intact artery results in lipid deposition and vascular cell adhesion molecule-1 upregulation in both LPL and ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:197–203.
30.
Michaud SE, Renier G: Direct regulatory effect of fatty acids on macrophage lipoprotein lipase. Diabetes 2001;50:660–666.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.